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Abstract
Developing a drug requires large investments, over many years, with dramatic increases in
development costs at later stages. Thus, one wants to make a No Go decision on a compound
early, unless evidence continues to suggest that the project will ultimately be successful, so that
resources can be focused on the most promising compounds to benefit patients. Instead of
predicting the probability of success of a Phase III study, our approach to this decision uses the
Phase II study results to assess similarity of the novel compound to existing drugs that are
classified by different decision categories, such as a clear Go decision (e.g., a clearly effective
drug), a (unfortunately common) Not Sure decision (e.g., a potentially useful but not outstanding
drug), and a clear No Go decision (e.g., a clearly not effective drug). We describe how this
modeling can be done using both individual and binary endpoints and how results can be
combined for several different endpoints. Potential extensions of the method are also discussed.
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1. Introduction
Consider the problem of a decision maker with a drug portfolio deciding whether to proceed
with a substantial investment for Phase III clinical trials for a compound. Ideally, this
decision would be made such that the expected value of proceeding with the specific
compound maximizes the entire value of the drug portfolio given all the other potential uses
of the funds, especially to invest in other compounds at earlier stages of development. Such
a calculation for this compound alone requires other factors that usually include an
assessment of the probability of technical success in the Phase III program, meaning both a
clinically important and statistically significant effect for specific endpoints in at least one,
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and normally two clinical trials, as well as an assessment of the likelihood of approval of the
drug based on its benefit–risk profile (Spiegelhalter, Abrams, and Myles 2004).
Clearly, this is a difficult decision problem that involves the true (unknown) benefit of the
compound, often for different endpoints than those already studied. For example, long-term
endpoints may be required for the regulatory filing rather than the short-term surrogate
endpoints used in the Phase II study. In addition, often different populations of patients will
be included in the Phase III studies. Thus, even assessing the probability of success in a
single Phase III study from the Phase II study results is a major challenge (Chan et al. 2008).
An alternative approach is to assess whether the compound seems to be similar to other
drugs that have been approved in the past for similar indications, or whether it appears
similar to compounds that ultimately did not become approved or were commercially
unsuccessful. Therefore, in this approach, we are estimating the probability that the
experimental compound is like the other compounds. This changes the decision process
from estimating the probability of success of the proposed Phase III study to classifying the
experimental compound as similar to one of several existing compounds. One implication of
this alternative approach is that the specifics of the Phase III study design are not taken into
consideration in the decision process. We pursue this approach in this article.
This article is organized as follows. Section 2 introduces the basic issues and notation, and
describes the basic model for binary endpoints. Section 3 provides an approach to
combining results from multiple endpoints and/or multiple studies. Section 4 provides an
illustration with hypothetical and real data combining results across three endpoints, and
Section 5 discusses potential extensions to the approach. The final section provides a brief
discussion of the potential advantages and disadvantages of the approach.
2. Notation and Basic Models
2.1 Assumptions
We assume that we have results from a randomized, parallel-group Phase II study
comparing the compound of interest against a control arm. We assume binary outcomes in
most of this article, and discuss additional extensions in Section 5. We assume further that
the decision maker has available data for one or more other products for the same or a
similar indication, so that there is at least some information on what was and was not
considered sufficient benefit to justify a drug approval in the indication of interest. This
prior information will usually consist of publications or presentations describing the benefit
for other compounds previously studied, and possibly regulatory guidance or
recommendations on what would be considered minimally adequate evidence for a
submission. We assume also that the decision maker can formulate the circumstances in
which they would be uncomfortable in making a decision based on the information from the
Phase II study; that is, when they would require additional information before making a
decision. Thus, we have changed the problem from one of determining the probability of
success to one of classification, determining the probability that the results for the
compound come from the class of successful drugs, of indeterminate information (or a
marginal drug), or of not successful drugs.
In summary, the following priors will be constructed, based on which the posterior
probability will be computed given the result from the Phase II study:
• Drug class prior: this is the prior distribution of a drug that leads to a clear Go
decision (e.g., a clearly effective drug), a Not Sure decision (e.g., a potentially
useful but not outstanding drug), and a clear No Go decision (e.g., a clearly not
effective drug).
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• Compound class prior: this is a prior that describes how likely is it that the
compound belongs to each of the three drug classes in decision makers’ minds.
Sometimes, a decision is based on multiple endpoints in a clinical trial, in which case it is
necessary to have an endpoint importance prior to indicate how important each of the
multiple endpoints is relative to the decision. This prior is also determined by decision
makers. The extension to multiple binary endpoints is discussed in Section 3.
2.2 Drug Class Prior
The benefit of the compound is the difference in the response between treatment groups.
Thus, the natural metric for the decision maker is the treatment effect ( ), rather than the
individual response rates in the two groups. We use  to classify the results of our Phase II
study as similar to one or another of the approved drugs. We do not allow for the possibility
of a negative  in our model since there would be no interest in pursuing a drug with an
unfavorable effect.
Three drug class priors are considered: a Go drug class (G), a Not Sure drug class (I), and a
No Go drug class (N). Since the true treatment effect δ ranges from 0 to 1, we define the
distribution of δ for each of the three drug classes as a beta distribution, Beta(ai,bi), i = G, I,
or N, where ai and bi are obtained based on the results of what our clinical colleagues
considered the characteristic study for the drug underlying the decision class, or based on a
meta-analysis of multiple independent studies.
2.3 Compound Class Prior
It is likely that the decision maker has some prior beliefs about the compound’s utility, and
that these views would tend to influence the decision. For example, the decision maker may
feel before a formal analysis that this specific compound is strong and therefore have an
optimistic prior with larger weight on the Go decision (dG), and relatively less weight on the
other two decisions (dI, dN). Alternatively, the decision maker may be very pessimistic
about the compound, or be relatively neutral and weight the three outcomes equally before
having the results of the Phase II studies, with the constraint that
Since the compound class prior is how strongly the decision maker feels about the
compound before having the data from the current study, it can be based on any approach
the decision maker wants to use and sometimes can incorporate various types of “extra”
information. There is no right or wrong prior, and it can be different for different decision
makers.
2.4 Phase II Study Result
For a binary endpoint, the data available would be the number of subjects having a response,
rA and rC (active and control, respectively) from nA and nC participants on study. The
outcome is the proportion responding,  and , and the effect of active
treatment is measured by . We assume throughout that benefit of the new
compound compared to the control is coded positively, that is, .
2.5 Transformation of the Observed Data for Analysis
Since we are modeling the probability that the observed difference, , comes from one of
the three underlying beta distributions, we need to convert the results of the original Phase II
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study into equivalent results for a conceptual experiment in which we would have observed
the outcome . The conceptual experiment would be a single arm study where the observed
outcome is the difference between the outcome with treatment and with control. Thus, the
results of the Phase II study (rA/nA, rC/nC) need to be converted into an equivalent set of
results ( ) as if the outcome ( ) was observed from a single arm study where the values
of  responses from  observations should have the same mean and asymptotic standard
error as the results from the parallel-group study. To do this, we first solve for the equivalent
number of observations  given the observed proportion difference so that the variance is
the same as the observed data; that is,
and then solve for
This transformation will fail if  is negative, but in that case there would be little interest in
pursuing the result. Let  and  be the nearest integers to  and , the results of the
conceptual experiment with a single arm being used in place of our original Phase II
parallel-group study. For example, suppose rA = 110, rC = 50, and nA = nC = 200, then
, , and .
In reality, even though a study is planned=to recruit a specific number of subjects, often the
actual number enrolled and evaluable differs slightly from the target. Thus, strictly speaking,
both nA and nC in the original experiment are random variables, but this complication is
ignored in most analyses. Similar to this conventional assumption, we consider that the
number of observations in our conceptual trial, , is preplanned, so that only  is a random
variable.
2.6 Modeling for a Single Binary Endpoint
Given the assumptions above, for the decision distribution i, the probability of observing 
responses from  (fixed) trials follows a beta-binomial distribution, that is,
, where p is a random variable that follows a beta distribution
for decision prior i, . Thus,
Then the probability that the results arise from distribution i is given by:
(1)
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Using the beta-binomial gives a single unique value for the result. However, we recommend
that these posterior probabilities be evaluated using Markov chain Monte Carlo (MCMC)
methods (Gilks, Richardson, and Spiegelhalter 1995) via WinBUGS, or SAS, for example.
Using simulations allows additional information to be provided to decision makers, which
becomes important when the results are close to the Go/No Go boundary. For example, in
addition to knowing what the average result is, decision makers might want to know what
fraction of simulations is above the boundary. Furthermore, simulations can easily be
extended for multiple endpoints as discussed in the next section and other extensions
described in Section 5.
3. Extensions to Multiple Binary Endpoints
Assume that we now have data and priors available on m endpoints (m > 1). Although an
active treatment is likely to improve results on multiple different endpoints, while an
inactive treatment is likely to have minimal impact on all endpoints, we ignore at this stage
the problem of potential correlation between the endpoints. We discuss an extension to the
analysis allowing for correlation in Section 5.
It is unlikely that all endpoints would be equally important in the decision to proceed with
drug development. As an illustration, a strong signal in the primary clinical endpoint used
for regulatory decisions would be far more important to the decision than would a patient-
reported health-related quality-of-life outcome.
There are at least two potential approaches for summarizing the results of the different
endpoints. The simplest approach would be a weighted average of the probabilities
separately estimated from decision i for endpoint j, denoted by Pj(i). Unlike Equation (1),
Pj(i) is calculated without incorporating the decision maker’s weights, since the weights
should be incorporated only once in the overall decision in Equation (3). With an obvious
extension of notation, therefore, Pj(i) is given by
(2)
where each  is a random draw from the beta-binomial distribution for
decision i and endpoint j.
Let ej, j = 1 …, m denote the relative weights for endpoint j with a constraint ∑jej. The
weighted average of the results, incorporating the decision maker’s weights, would then give
the overall probability that the drug belongs to class i by
(3)
Again, a single unique value could be calculated if desired, using the beta-binomial formula,
but again this would seem to neglect the potential for variability in the results.
An alternative approach would be based on the likelihood for each endpoint. We do this in
the MCMC framework as follows. We draw a random sample from the corresponding beta
distribution for decision i and endpoint j denoting the kth set of such draws by θi,j,k. We
calculate, for each of the observed results (  events among  observations), the overall
likelihood kernel of the results for this draw,
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The probability that the set of results come from decision i for that specific draw would then
be given by
(5)
and the overall result would be the summary of these results.
4. Example
We applied the proposed method to a Phase II dose ranging study where patients were
equally randomized to a placebo group or one of three dose groups. The analysis was
focused on the comparison of three binary efficacy endpoints between the highest dose
group and the placebo group.
4.1 Drug Class Prior
Three drug classes were denoted as G-like (a Go decision), I-like (a Not Sure decision), and
N-like (a No Go decision). The drug class prior was constructed based on the following
steps: (1) A review was conducted for historical studies that our clinicians would consider
representative for the underlying decision classes (see Section 2.2). In this example, about
two to six studies were reviewed for each drug class and a typical study was chosen to
represent the corresponding drug class. (2) The observed proportion difference from the
study chosen for each drug class was then converted into a result from an equivalent single
arm study. Suppose the response rates from a study for the N-like drug class are rA = 95 and
rC = 55 and the sample sizes are nA = 250 and nC = 251 for active and control groups,
respectively. Using the same method as described in Section 2.4, we obtain  and
. (3) The parameters of the beta distribution were calculated. For the N-like drug
class, the parameters are  and  for the beta distribution.
Figure 1 shows a set of decision distributions for each endpoint by three curves: green for a
Go decision; orange for a Not Sure decision; and red for a No Go decision. These colors are
used throughout the figures. As is typical in our experience, there is considerable overlap
between adjacent decisions, and even modest overlap between the Go and the No Go
decision. This emphasizes the importance of using multiple criteria for making the decision.
4.2 Compound Class Prior
The decision makers may have different prior beliefs about how likely it is that the
investigational drug would fall in each drug class, in which case sensitivity analyses should
be performed as shown in Table 1. As a primary analysis, the key decision maker’s beliefs
are used, dG = 0.2, dI = 0.6, and dN = 0.2; that is, a much stronger belief on a I-like drug. In
a sensitivity analysis, different beliefs (neutral, optimistic, or skeptical) were also used and
results are presented in Table 1.
4.3 Endpoint Importance Prior
The endpoint importance was unanimous among decision makers that there was a modest
differential weighting of the three endpoints, with the second endpoint considered the most
important with 50% of the total weight, the first endpoint being counted as 30%, and the last
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endpoint being counted as 20%. The Win-BUGS code used for the calculations is attached
in the Appendix. Each simulation was run using 20,000 MCMC iterations.
4.4 Results and Decision Making
Figures 2 and 3 show two sets of hypothetical results. Figure 2 intends to show a difficult
decision situation where it is very unclear how strong the data are for the Go decision. For
each endpoint, the results are close to a 50:50 decision, reflecting results close to the mid-
point of overlap between the Go and the Not Sure decisions shown in Figure 1. Since there
is no strong signal for any of the three endpoints, both the weighted average and weighted
likelihood approaches reflect that the overall results are not clear. Figure 3 shows a much
clearer result for the individual endpoints. In both cases, the weighted likelihood approach
increases the magnitude of the difference between the two choices compared to the
averaging approach, emphasizing the consistency of the results in the three endpoints.
Figure 4 shows the real results of the Phase II study. The drug is similar to N-like drugs with
a probability of 87% or higher for endpoints 1 and 2, while the probability is about 83% for
endpoint 3. The similarity to G-like drugs is as low as 1%. The overall estimates, after
taking into account the weighting of the three endpoints, show clearly that this would be a
No Go decision.
As a robustness check of the primary analysis, we also assume a neutral opinion, an
optimistic prior, and a skeptical prior, in addition to the key decision maker’s belief. Table 1
displays the weighted likelihood estimates of the probabilities based on various compound
class priors. Prior opinions about the drug do change the results, but even very strong prior
beliefs about the drug do not overwhelm the data. In conclusion, it is unlikely that the
compound is as effective as a G- or I-like drug and clearly is an N-like (No Go) drug.
5. Extensions
We briefly mention several potential extensions of the method, without providing specific
details of any of them. The most obvious extension would be to other types of endpoints; for
example, normally distributed endpoints and time-to-event data. These types of endpoints
can easily be modeled using standard approaches for Bayesian data analysis available in
existing software, and present no additional problems to the methods presented above.
Another obvious extension would be when there are, as usually occurs, multiple preliminary
and Phase II studies, usually in somewhat different indications or in different patient
populations, possibly with different compound posology. The problem becomes how
relevant the results in these other studies would be for the current decision, and the decision
maker must provide information on this. Often the results of these other studies are
ultimately considered of modest value for the decision. Depending on the specifics of the
situation, it may be necessary to analyze the results using priors for the different decisions
specific to each study, since the success criteria may well be substantially different across
different indications and populations. Results of these analyses could then be presented
separately, as a type of sensitivity analysis, or combined with explicit weights based on the
decision maker’s assessment of the importance of the individual studies, similar to the
approach illustrated with the weighted likelihood approach across multiple endpoints shown
in Equation (5). A third approach would be to assume an underlying hierarchical model,
with each of the specific prior studies a realization from the hyperdistribution of the decision
classes. One would then use the different study results to estimate the parameters of the
hyperdistribution, and then use the hyperdistribution as the observed data to estimate the
probabilities of the various decision classes (Chen and Ibrahim 2006).
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A third area for extension would be the common case where there are multiple potential
studies available on other treatments that could be used for priors for the different decisions.
There are several ways that this can be approached as mentioned above in the case of using
results from more than one preliminary study. We recommend that the results be analyzed
separately for each of these individual studies to assess the consistency of the decision.
Obviously, if very different decisions would be made depending on which prior study is
used (e.g., clear evidence for a Go decision with one study, and a No Go decision with
another), then this is critical information for the decision maker.
A fourth area for extension would explicitly model the unreliability of the results in the
specific Phase II study itself. For example, the distribution of the true underlying probability
of success for a binomial endpoint based solely on the Phase II study is given by a Beta(rδ +
1,nδ-rδ + 1) distribution. One could potentially sample from this underlying distribution,
denoting the kth sample by Θk, sample rδ,k from a binomial distribution with parameters Θk
and nδ, and then estimate the probability of class membership using Equations (1) or (4) and
(5), based on this sample.
Finally, there is the extension to correlations among the different endpoints. This raises
several issues. First, when simulating results from the prior distributions, results of one
endpoint would need to be incorporated in the generation of a sample from the second prior.
This assumes that there is a causal model; for example, that endpoint 1 affects endpoint 2,
rather than solely a correlation, so that one knows how to model the sampling. Second, it
becomes less clear what weights are actually being applied to the different endpoints. In
particular, the weight attached to the second endpoint provides additional weight on the first
endpoint assuming a positive association. Determining the actual weight in this case would
be challenging. Expanding associations to more than two endpoints would be even more
challenging.
6. Discussion
We have outlined a basic approach for deciding whether to proceed to a Phase III program,
based on the chance that the treatment being developed resembles existing treatments. We
have framed the problem as classifying the Phase II results as similar to a successful
treatment (a “Go” decision), an unsuccessful treatment (a “No Go” decision), or as one in
which further information is required (based on similarity to a “marginal” product). The
approach can handle single or multiple endpoints of various kinds; we give formulas for
binary outcomes, but the approach can easily be extended to other endpoints and
combinations of endpoints as well. The approach can explicitly incorporate the relative
importance of different endpoints, as well as the decision maker’s prior opinions about
whether the treatment would be successful or not. The approach described here has provided
useful guidance to the decision-making process.
There are several advantages to our approach. First and foremost, it forces clear thinking
about how to make the decision. Most importantly, it forces decision makers to clearly
identify what success looks like for the treatment. In addition, it focuses attention on the
importance of different endpoints in this decision. This is particularly important as there is
sometimes a tendency to define success post hoc, after the results are available. Our
approach encourages systematic background data collection, so that priors can be formed for
the different drug classes. By assessing the results using different potential priors for the
decision classes, it is possible to assess the sensitivity of the results to assumptions regarding
the definition of success. Furthermore, our approach allows different decision makers to use
different priors, to weight endpoints differently, and to have different prior probabilities as
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to the likely success of the treatment. This allows the impact of these different assumptions
to be explicitly recognized.
Our approach is fundamentally different from an approach in which the results of the Phase
II study are used to predict the success of the Phase III study. To do this requires
assumptions about the nature of the relationship between the Phase II endpoint and the
Phase III endpoint required for regulatory approval and about the impact of patient
characteristics on both the Phase II and Phase III endpoints, among other things. Such an
approach attempts to answer the question “will the Phase III study be successful?” In
contrast, our approach answers the question “does this treatment look like other successful
treatments?” Although definitely not the same question, the information can be viewed as a
necessary, but not sufficient, condition for success.
Our approach requires extensive data collection, which can be difficult, time consuming, and
expensive. It could be hard to find the relevant information on other compounds, especially
if the Phase II study involves short-term surrogate endpoints for decision making, rather
than longer-term endpoints used in Phase III trials, which is often the primary information
available in the published literature. In addition, the data abstraction/reduction may on
occasion reduce the problem to one or at most a very small number of dimensions, which
would give these endpoints more importance than they might deserve. Although we have
focused on combining efficacy endpoints, the approach can be extended easily to
incorporate different dimensions, such as targeted safety signals when there is an issue with
other drugs having the same mechanism of action, for example.
Finally, it is important to realize that by quantifying the classification problem, we may well
lead decision makers to focus on the posterior probabilities from our approach rather than in
the broader decision itself. Thus, it is important when presenting results from this approach
that the robustness and variability of estimates be emphasized at least as much as the
estimates themselves. Given the magnitude and expense of a Phase III program, it is
essential to emphasize that these results, although quantified, should be only one aspect of
the overall decision.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Sample endpoint decision criteria.
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Key decision makers belief
 20%, 60%, 20% 0.908 0.090 0.002
Neutral belief: 33%, 33%, 33% 0.960 0.038 0.003
Optimistic belief: 5%, 20%,
 75% 0.861 0.109 0.029
Skeptical belief: 75%, 20%, 5% 0.988 0.011 0.000
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